Azithromycin for the treatment and control of trachoma

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 2, 2002, Pages 113-120

  Burton, M J ^a   Frick, K D ^a   Bailey, R L ^a   Bowman, R J C ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antibiotics; Azithromycin; Blindness; Tetracycline; Trachoma

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; MACROLIDE; OXYTETRACYCLINE; POLYMYXIN B; QUINOLONE DERIVATIVE; RIFAMPICIN; SULFONAMIDE; TETRACYCLINE;

ADULT; ANTIBIOTIC THERAPY; BLINDNESS; CHILD; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CLINICAL TRIAL; CONJUNCTIVITIS; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; ENDEMIC DISEASE; FEVER; FREQUENCY ANALYSIS; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INFECTION CONTROL; PATIENT COMPLIANCE; REVIEW; TRACHOMA; TREATMENT FAILURE; VOMITING;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BLINDNESS; CHLAMYDIA TRACHOMATIS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; HUMANS; TRACHOMA;

EID: 0036173021     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.2.113     Document Type: Review

References (44)

1. Global initiative for the elimination of avoidable blindness
2. The microbial epidemiology of trachoma
3. Guide to trachoma control
4. The duration of human ocular Chlamydia trachomatis infection is age dependent
5. Global data on blindness
6. Trachoma through history
7. The epidemiology of trachoma predicts more blindness in the future
8. Extraocular infections in children in areas with endemic trachoma
9. The winning hand to defeat trachoma
10. Azithromycin - Review of key chemical, pharmacokinetic and microbiological features
11. Comparison of the acid stability of azithromycin and erythromycin A
12. The pharmacokinetics of azithromycin in human serum and tissues
13. Tissue-directed pharmacokinetics
14. Spectrum of activity of azithromycin
15. Vitro activity of azithromycin against Chlamydia trachomatis
16. Vitro activity of azithromycin, erythromycin, ciprofloxacin and norfloxacin against Neisseria gonorrhoeae, Haemophilus ducreyi, and Chlamydia trachomatis
17. A controlled trial of a single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis
18. Ocular levels of azithromycin
19. Pharmacokinetics of azithromycin in trachoma patients: Serum and tear levels
20. Randomised controlled trial of single-dose azithromycin in treatment of trachoma
21. Single-dose azithromycin in the treatment of trachoma. A randomized, controlled study
22. A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children
23. Operational comparison of single-dose azithromycin and topical tetracycline for trachoma
24. What clinical signs are critical in evaluating the intervention in trachoma?
25. Non-ocular Chlamydia infection and risk of ocular re-infection after mass treatment in a trachoma hyperendemic area
26. Persisting in apparent chlamydial infection in a trachoma endemic community in The Gambia
27. Azithromycin in control of trachoma
28. Clinical toleration and safety of azithromycin
29. Impact of community-based mass treatment for trachoma with oral azithromycin on general morbidity in Gambian children
30. Effects of azithromycin on malariometric indices in the Gambia
31. Future approaches to trachoma control - Report of a global scientific meeting
32. Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure
33. A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae
34. Impact of azithromycin on oropharyngeal carriage of group A Streptococcus and nasopharyngeal carriage of macrolide-resistant Streptococcus pneumoniae
35. Impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae
36. Alterations in the conjunctival bacterial flora following a single dose of azithromycin in a trachoma endemic area
37. The SAFE strategy for the elimination of trachoma by will it work?
38. Analysis of the household distribution of trachoma in a Gambian village using a Monte Carlo simulation procedure
39. Comparison of two azithromycin distribution strategies for controlling trachoma in Nepal
40. Cost-effectiveness of trachoma control measure: Comparing targeted household treatment and mass treatment of children
41. Pilot study of the use of community volunteers to distribute azithromycin for trachoma control in Ghana
42. Global elimination of trachoma: How frequently should we administer mass chemotherapy?
43. Review of the evidence base for the 'F' and 'E' components of the SAFE strategy for trachoma control